Epstein-Barr Virus (EBV)
Vaccines Commercial Forecast
Epstein-Barr virus infects the vast majority of the world's population and is now recognised as a requisite risk factor for multiple sclerosis, alongside its established causal role in infectious mononucleosis and a growing list of cancers. After decades without a licensed vaccine, Moderna's mRNA-1189 and mRNA-1195 candidates have brought EBV prevention back to the front of the pipeline. This is the independent commercial assessment of the opportunity, drawing on VacZine Analytics' long-standing, independent authority in the adolescent and STD vaccine markets.
- Format
- PDF + Excel model
- Coverage
- Adolescent & young-adult
- Vaccines assessed
- mRNA-1189, mRNA-1195
- Markets
- Public & private
- Approach
- Scenario-based
- Base edition
- April 2022
- Availability
- Syndicated / bespoke
infected with EBV for life
cases worldwide each year
following EBV infection
clinical development
Why EBV has become a vaccine priority again
Epstein-Barr virus has moved from a near-universal, largely tolerated childhood infection to one of the most consequential targets in the vaccine pipeline. Understanding its epidemiology, and the very different reasons for vaccinating against it, is central to understanding the size and shape of the commercial opportunity.
Pathogen overview - Epstein-Barr virus (EBV)
Epstein-Barr virus, formally human gammaherpesvirus 4, is one of nine human herpesviruses and among the most ubiquitous pathogens in existence, infecting more than 90% of the global population at some point in their lives. Transmitted principally via saliva, hence its colloquial name, the kissing disease, EBV establishes lifelong latency in B lymphocytes following primary infection, a persistence that underlies both its chronic disease associations and the practical difficulty of designing a vaccine against it.
EBV's epidemiology follows two quite different patterns. In lower- and middle-income settings, primary infection typically occurs before age three and is almost always asymptomatic. In higher-income settings, infection is frequently delayed to adolescence or young adulthood, with seroprevalence exceeding 80% by ages 18 to 19 in the United States, and delayed primary infection produces symptomatic infectious mononucleosis in a substantial share of cases. US incidence of infectious mononucleosis runs at roughly 500 per 100,000 population overall, rising to 200 to 800 per 100,000 among 15 to 24 year olds, precisely the population this vaccine class targets.
The single most consequential epidemiological finding of the past decade concerns multiple sclerosis. A longitudinal analysis of over ten million young US military personnel found that the risk of multiple sclerosis increased 32-fold following EBV infection, and more than 99% of MS patients are EBV-seropositive, against 90 to 95% of the general population. EBV is now considered a requisite, though not on its own sufficient, risk factor for MS. That finding has transformed a vaccine once framed narrowly around adolescent mononucleosis prevention into a candidate strategy for preventing one of neurology's most burdensome autoimmune diseases, precisely the rationale behind Moderna's second-generation mRNA-1195 candidate.
EBV also carries a well-established causal role in several cancers: nasopharyngeal carcinoma (nearly all cases worldwide), Burkitt lymphoma, a subset of Hodgkin and non-Hodgkin lymphoma, gastric cancer and post-transplant lymphoproliferative disease. Across six major EBV-associated cancers, global estimates range from around 240,000 to 360,000 new cases and 140,000 to 210,000 deaths annually. Despite this burden, there is still no licensed vaccine and no EBV-specific antiviral therapy; management today remains entirely supportive.
Four decades of failure - and two mRNA candidates changing the picture
EBV vaccine development has a long history of promise and disappointment. GSK's gp350 subunit vaccine and Merck's tetravalent V419 both stalled years ago. Moderna's mRNA platform has now put two candidates back into the clinic, backed by a commercial rationale that extends well beyond mononucleosis, and in May 2026 Eli Lilly entered the field directly, agreeing to acquire Vaccine Company, Inc. and its Phase 1-ready EBV candidate for up to $1.55bn.
-
ModernaLead candidatemRNA-1189 Phase 1
Prophylactic mRNA vaccine encoding four EBV surface glycoproteins (gH, gL, gp42 and gp220/gp350), designed to block both the epithelial-cell and B-cell entry routes the virus uses to establish infection. The Phase 1 trial in 10 to 30 year old adolescents and adults read out positively, with a stronger immune response reported than natural infection produces; a further Phase 1 study in 18 to 30 year olds began March 2026. Moderna has indicated the candidate is advancing toward pivotal development. -
ModernaPhase 1/2mRNA-1195 Second generation, MS-focused
A second-generation candidate that has now advanced beyond its original Phase 1 volunteer study (18 to 55 year olds): per Moderna's June 2026 Science Day update, a Phase 2 safety and dose-ranging study in adults with early relapsing multiple sclerosis is underway, its sentinel cohort fully enrolled, with the trial's Data Safety Monitoring Board recommending dose escalation; the companion Phase 1 study (Part A/Part B, NCT05831111, 482 participants) has since completed, per ClinicalTrials.gov, with a study-completion date of 14 October 2026 and its record updated to Completed status on 4 November 2026; full Part B results have not yet been posted. The programme is positioned with an explicit eye on the multiple sclerosis prevention rationale opened up by the 2022 EBV-MS causality data, in addition to standard mononucleosis prevention. -
Eli LillyNew entrant, May 2026Vaccine Company, Inc. EBV programme Phase 1-ready
Lilly agreed in May 2026 to acquire Vaccine Company, Inc., a Global Health Investment Corporation portfolio company, for up to $1.55bn in upfront and milestone payments, gaining a five-antigen, Phase 1-ready EBV candidate built on the firm's proprietary In Vivo Nanoparticle (IVN) platform, which displays antigens in virus-like-particle format via a simplified manufacturing route. Lilly cited the mononucleosis, MS and EBV-linked malignancy rationale explicitly; the deal was announced alongside two other Lilly infectious-disease acquisitions the same day. Subject to Hart-Scott-Rodino antitrust review. -
GSKDiscontinuedgp350 subunit vaccine (historical)
The most clinically advanced EBV vaccine of the pre-mRNA era. A 2007 randomised trial showed a 78% reduction in infectious mononucleosis, but no reduction in underlying EBV infection rates, an efficacy pattern that continues to shape how the whole field now thinks about realistic vaccine endpoints. Development was discontinued. -
MerckDiscontinuedV419 (historical)
A tetravalent gp350 and gH/gL vaccine candidate that reached Phase 1 before development was discontinued on immunogenicity grounds. A key historical data point informing dose and antigen-combination decisions in current mRNA programmes. -
NIH / NIAIDPhase 1gp350-ferritin nanoparticle
A self-assembling nanoparticle vaccine displaying gp350 at high density, designed to improve on the modest immunogenicity of earlier monomeric subunit approaches. First-in-human data are informing the broader academic and biotech nanoparticle pipeline. -
Second-wave academic & biotech pipelineVariousMultivalent gB/gH/gL/gp350 nanoparticle and next-generation mRNA constructs
Sustained academic and biotech interest in a target once considered commercially unattractive, now reframed by the MS-prevention rationale and the mRNA platform's improved immunogenicity profile.
The 2022 finding that EBV infection increases multiple sclerosis risk 32-fold transformed the commercial logic of this market overnight. A vaccine once framed narrowly around adolescent mononucleosis prevention is now a candidate strategy for preventing one of neurology's most burdensome autoimmune diseases, and Moderna's mRNA-1195 programme is built explicitly around that rationale. The VacZine Analytics model quantifies the commercial upside of both the mononucleosis-prevention and MS-prevention framings.
Six analytical layers - one commercial picture
The MarketVIEW EBV analysis spans disease burden, target-population rationale, the mRNA-1189 and mRNA-1195 vaccine profiles and scenario-based revenue forecasting across public adolescent immunisation and private channels.
Target-population sizing for routine adolescent immunisation, mirroring HPV and other adolescent vaccine programme design, alongside private and occupational channels.
Head-to-head assessment of mRNA-1189 and mRNA-1195 against the historical gp350 and V419 record, informing realistic efficacy-endpoint assumptions.
A separate scenario in which payers and policymakers price in downstream multiple sclerosis risk reduction, not just mononucleosis avoidance.
Base, upside and conservative scenarios across public adolescent immunisation programmes and private travel and occupational channels.
Updated global seroprevalence, infectious mononucleosis incidence, and the EBV-attributable cancer and multiple sclerosis burden.
Positioning against existing adolescent-schedule vaccines (HPV, MenACWY) for co-administration and budget-impact assumptions.
A glimpse of the commercial model
The table below shows a partial view of the target-population and scenario framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.
| Target population | Geography | Market type | Vaccine profile | Revenue scenario |
|---|---|---|---|---|
| Adolescents (10 to 19) | HI markets | Public programme | 2/3-dose mRNA | Modelled |
| Young adults (18 to 30) | Global | Private / occupational | 2/3-dose mRNA | Modelled |
| MS-risk reduction cohort | US + EU5 | Public + private | Booster / second-gen | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | Global | All | All profiles | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for decision-makers who need the full picture on the EBV vaccine opportunity.
- Executive presentation (PDF) - disease background, epidemiology, the 2022 MS-causality data, EBV-attributable cancer burden, vaccine profiles and full commercial assessment with supporting narrative and references
- Interactive MS-Excel forecast model - volume and revenue outputs with scenario toggles, target-population breakdowns and pricing assumptions across public and private markets
- Scenario-based commercial forecasts - base, upside and conservative cases spanning the mononucleosis-prevention and MS-prevention framings, with explicit assumptions
- Competitor intelligence - mRNA-1189 versus mRNA-1195 head-to-head, and the historical gp350 and V419 efficacy record
- Updated epidemiology module - global seroprevalence, infectious mononucleosis incidence, the EBV-MS causality data and the EBV-attributable cancer burden
- Adolescent & young-adult segmentation - public programme versus private and occupational channels, and co-administration positioning against existing adolescent-schedule vaccines
Built for organisations weighing the EBV opportunity
Most valuable to teams evaluating the EBV vaccine market against their own pipeline, BD ambitions or investment thesis, particularly in light of the MS-prevention rationale and Moderna's clinical progress.
Vaccine developers
Positioning, commercial feasibility and target-population prioritisation for EBV candidates at any stage.
Corporate strategy & BD
Validate the market size and structure across both the mononucleosis-prevention and MS-prevention framings.
Investors & analysts
Independent assessment of market size and pipeline risk for due diligence on EBV and adjacent herpesvirus assets.
Public health & immunisation programmes
Adolescent-schedule integration and demand modelling for national immunisation programmes.
Researchers & academia
Comprehensive epidemiology spanning virology, oncology and neurology, and the vaccine landscape for grant and translational planning.
Market access & policy
Pricing benchmarks and budget-impact assumptions against existing adolescent-schedule vaccines.
VacZine Analytics has tracked adolescent and STD-adjacent vaccine markets since our earliest editions, positioning us to reassess EBV the moment the underlying science changed. This analysis combines a rigorous epidemiological and clinical review with an independently constructed commercial model spanning the mononucleosis-prevention and MS-prevention framings that most forecasts still treat as separate questions. Few groups have followed the adolescent and STD vaccine space as closely or for as long, and that recognised, independent expertise underpins everything in the analysis.
This report was last fully published in April 2022, with supplementary notes added in September 2023 reflecting the emerging EBV-MS causality evidence. A full refresh, updating Moderna's mRNA-1189 and mRNA-1195 clinical progress and reassessing the MS-prevention commercial case, is available on syndicated or bespoke terms. The syndicated route proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc EBV analysis, a briefing call is included on request.